Juno Therapeutics, Inc.

Juno Therapeutics, Inc.

Juno Therapeutics, Inc.

Overview
Date Founded

2013

Headquarters

400 Dexter Avenue North, Suite 1200, Seattle, WA, 98109, USA

Type of Company

Private

Employees (Worldwide)

663

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals
Medical Support Services

Company Description

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Contact Data
Trying to get in touch with decision makers at Juno Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Financial Officer & Head of Corporate Development

General Counsel & Secretary

Chief Information Officer

Chief Medical Officer & Senior Vice President

President of Research & Development

Senior Vice President, Managing Director

Executive Vice President, Technical Operations

Senior Vice President, Manufacturing

Senior Vice President, Regulatory & Quality Assurance

Scientific Co-Founder

Board of Directors

Executive Vice President & Chief Corporate Strategy Officer at Celgene Corp.

Chairman & Chief Executive Officer at Celgene Corp.

Paths to Juno Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Juno Therapeutics, Inc.
Recent Transactions
Details Hidden

Celgene Corp. purchases Juno Therapeutics, Inc.

Details Hidden

Juno Therapeutics, Inc. issued USD Common Stock

Details Hidden

Juno Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors
Investment Advisor

Advised onCelgene Corp. purchases Juno Therapeutics, Inc.

Legal Advisor

Advised onJuno Therapeutics, Inc. purchases RedoxTherapies, Inc.

Underwriter

Advised onJuno Therapeutics, Inc. issued USD Common Stock

Associate

Advised onJuno Therapeutics, Inc. issued Common Stock

Associate

Advised onJuno Therapeutics, Inc. issued Common Stock

Underwriter

Advised onJuno Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Scientific Advisor

President at Stanford University

Legal Advisor

Managing Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Clients

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Key Stats and Financials As of 2017
Market Capitalization
$8.21B
Total Enterprise Value
Earnings Per Share
Revenue
$112M
EBITDA
$-424M
Investments
Details Hidden

JW Therapeutics (Shanghai) Co. Ltd. develops cell-based immunotherapies to treat cancer. The company was founded by Yiping Li and is headquartered in Shanghai, China.

Investors
Details Hidden

Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private cancer center — has devoted more than 125 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 41 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and biomedical research around the world.

Details Hidden

ARCH Venture Partners focuses on seed and early-stage investments in start-up technology companies, with a particular interest in the life sciences, the physical sciences and information technology. Their life sciences investments focus on biotechnology, pharmaceuticals, medical instrumentation and informatics. Their physical sciences investments focus on companies that are pioneering technology with a range of commercial applications in chemicals/materials, electronics/instrumentation and medical instrumentation industries. The firm's focus within the information technology sector includes electronics/hardware, information, infrastructure/software and commerce. ARCH Venture Partners invests primarily in companies located in the southwestern, Midwestern, eastern seaboard and northwestern sections of the US. The firm exits most of their investments through IPOs or private sales.

Details Hidden

Explore Holdings invests in companies located in the US. The firm provides financing for seed and early stage capital requirements.

Suppliers
Fred Hutchinson Cancer Research Center Hospitals & Patient Services | Seattle, WA

Fred Hutchinson Cancer Research Center provides research services for the prevention, early detection, and treatment of cancer and other diseases in the United States and other countries. The research center is engaged in researches to prevent, detect, and treat cancer, HIV/AIDS, and other life-threatening diseases. Its activities in the areas of diseases and research cover fundamental research, prevention, early detection, treatment and cures, and survivorships. Researchers of Fred Hutchinson Cancer Research Center pioneered bone-marrow transplantation for leukemia and other blood diseases. This research has cured thousands of patients worldwide and has boosted survival rates for certain forms of leukemia from zero to 85 percent.

Seattle Children's Hospital Hospitals & Patient Services | Seattle, WA

Seattle Children's Hospital delivers superior patient care, advance new discoveries and treatments through pediatric research and serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. In 2015, U.S. News & World Report ranked Seattle Children’s No. 6 in the country among the nation’s best children’s hospitals.

St. Jude Children's Research Hospital, Inc. Medical Support Services | Memphis, TN

St. Jude is unlike any other pediatric treatment and research facility. Discoveries made here have completely changed how the world treats children with cancer and other catastrophic diseases. With research and patient care under one roof, St. Jude is where some of today's most gifted researchers are able to do science more quickly. The mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder Danny Thomas, no child is denied treatment based on race, religion or a family's ability to pay. Our vision is to be the world leader in advancing the treatment and prevention of catastrophic diseases in children. This vision will be pursued by providing outstanding patient care; by conducting basic, translational and clinical research designed to elucidate biological mechanisms, understand disease pathogenesis, improve diagnosis, enhance treatment outcome, prevent diseases and minimize adverse consequences of treatment; and by educating health care and scientific research professionals. Through these efforts we seek to cure and enhance the quality of life for an increasing proportion of children who come to us for treatment, and by expanding and sharing knowledge, to advance treatment of children with catastrophic diseases worldwide, while developing strategies to prevent catastrophic diseases in children.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Juno Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Juno Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Juno Therapeutics, Inc..